Editing Diabetic retinopathy (section)

===C-peptide===
[[C-peptide]] had shown promising results in treatment of diabetic complications incidental to vascular degeneration.<ref>{{cite journal | vauthors = Bhatt MP, Lim YC, Ha KS | title = C-peptide replacement therapy as an emerging strategy for preventing diabetic vasculopathy | journal = Cardiovascular Research | volume = 104 | issue = 2 | pages = 234–244 | date = November 2014 | pmid = 25239825 | doi = 10.1093/cvr/cvu211 | doi-access = free }}</ref> Creative Peptides,<ref>{{cite web|title=C-peptide - Creative Peptides -|url=http://adisinsight.springer.com/drugs/800010430|publisher=AdisInsight|access-date=22 October 2016}}</ref> Eli Lilly,<ref>{{cite web|title=C-peptide – Eli Lilly|url=http://adisinsight.springer.com/drugs/800005551|publisher=AdisInsight|access-date=22 October 2016}}</ref> and Cebix<ref>{{cite web|title=C-peptide long-acting – Cebix|url=http://adisinsight.springer.com/drugs/800034107|website=adisinsight.springer.com|publisher=AdisInsight|access-date=22 October 2016}}</ref> all had [[drug development]] programs for a C-peptide product. Cebix had the only ongoing program until it completed a Phase IIb trial in December 2014 that showed no difference between C-peptide and placebo, and it terminated its program and went out of business.<ref>{{cite news| vauthors = Bigelow BV |title=Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug|url=http://www.xconomy.com/san-diego/2015/02/23/cebix-shuts-down-following-mid-stage-trial-of-c-peptide-drug/|work=Xconomy|date=23 February 2015}}</ref><ref>{{cite news| vauthors = Garde D |title=Cebix hangs it up after raising $50M for diabetes drug|url=http://www.fiercebiotech.com/r-d/cebix-hangs-it-up-after-raising-50m-for-diabetes-drug|work=FierceBiotech|date=February 24, 2015}}</ref>